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Abstract
Purpose The purpose of this study is to describe the
clinical characteristics, microscopic findings, and treatment
response to albendazole of microsporidial keratoconjunctivitis
among immunocompromised individuals with HIV/AIDS.
Methods This is a retrospective case series. Diagnosis of
microsporidial keratoconjunctivitis was confirmed by sub-
specialist examination and conjunctival swabs examined by
light microscopy. HIV infection was documented, and
absolute CD4+ T cell count was determined. Patients were
treated with albendazole and followed for clinical response.
Results Light microscopy from the conjunctival swabs
demonstrated myriad small, round to oval microsporidial
organisms that stained positively with modified acid-fast
methods. Two of the patients initially not taking highly
active antiretroviral therapy (HAART) and presenting with
an absolute CD4+ T cell count less than 100 cells/μL had a
more severe form of keratoconjunctivitis than the third
patient (receiving HAART, with a CD4+ T cell count of
259 cells/μL). All patients were started or continued on
HAART. Two of the patients responded to oral albendazole,
with resolution of symptoms and signs. The third patient
did not initially respond, perhaps because of an immune
recovery inflammatory syndrome, but subsequently had
temporary improvement with albendazole.
Conclusions Microsporidial keratoconjunctivitis is a rare
ocular complication of HIV/AIDS. Light microscopic
evaluation of conjunctival swabs may be a useful minimally
invasive first step toward diagnosis of microsporidial
keratoconjunctivis in settings where electron microscopy
is not available. Based on the limited available information,
albendazole often is effective for this condition, and is
widely available in developing countries at low cost.
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Introduction and literature review
Microsporidia are obligate intracellular spore-forming eu-
karyotic protozoan parasites, some of which are pathogenic
in humans [1]. They are ubiquitous in the environment, and
can infect a wide range of vertebrate and invertebrate hosts,
including insects, birds, fish, and mammals [2]. To date, up
to 150 genera containing over 1,200 species have been
described. Of these genera, six are known to infect human
beings: Encephalitozoon, Enterocytozoon, Nosema, Pleis-
tophora, and Trachipleistophora [3]. The spore is resistant
to degradation, surviving in the environment for up to
4 months [4] in its infective form. Humans acquire
infection through ingestion, inhalation, or sexual transmis-
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sion of spores [4]. Although reliable prevalence data are
lacking, recent studies indicate increased risk of micro-
sporidial keratoconjunctivitis in the rainy season [5].
It is not clear how microsporidia enter into the cornea;
traumatic inoculation or contact with contaminated water or
food has been suggested [4]. Once invasion of the spore
into the human host cell occurs, the contents are discharged
into the cytoplasm. Within the cell, the sporoplast divides
by binary fission to form a schizont with two to six nuclei,
which split into unicellular meronts. The meronts then
secrete a rigid capsule; the fully formed spore measures
about 2.5×1.5 μm. The cell eventually ruptures to continue
the cycle of further destruction of the host tissue [3].
Clinical symptoms and disease associated with micro-
sporidiosis vary with the species that causes the infection
and the host’s immune status [6]. Most cases of intestinal
and disseminated microsporidiosis in patients infected with
HIV are reported in patients who are severely immuno-
compromised (CD4+ T cell count <100/mm3); in these
patients, morbidity can be significant [7].
Microsporidial infections of the ocular surface in
humans are rare diseases. Microsporidial keratoconjuncti-
vitis has been described primarily in patients with HIV
infection [6], but also has been reported in normal hosts [5,
8]. There are two main clinical presentations of ocular
microsporidiosis: a necrotizing stromal keratitis that occurs
in immunocompetent individuals and an epithelial kerato-
conjunctivitis described in HIV-infected individuals [3, 6].
Bilateral punctuate epithelial involvement of the cornea
with white intraepithelial infiltrates that stain irregularly
with fluorescein is the typical pattern of ocular micro-
sporidiosis described in immunocompromised individuals
[6]. Deep stromal disease may or may not be present. Other
findings include a mild anterior chamber reaction and a
mild conjunctivitis. Presenting symptoms include foreign
body sensation, dryness, redness, reduced visual acuity, and
photophobia. Ocular surface disease appears to be less
severe when CD4+ T cell counts are low; with immune
reconstitution, signs and symptoms may become more
pronounced [6]. Although primarily described in patients
with AIDS, a pattern of ocular microsporidiosis with
minimal inflammatory signs also has been reported to
occur in immunocompetent individuals receiving topical
corticosteroid therapy [3–7].
Diagnosis of ocular microsporidiosis is based on scrap-
ings or biopsy of the conjunctiva or cornea. Pathologically,
microsporidial spores are ovoid and may be found in the
cytoplasm of the epithelial cells, sometimes measuring only
2×1 μm. There will be few accompanying inflammatory
cells in individuals with pronounced immunodeficiency.
The organisms are Gram positive and stain well with
Giemsa stain; characteristic periodic acid–Schiff-positive
granules are found in one end of the mature microsporidial
spores. Diagnosis may be aided by the use of electron
microscopy and confocal microscopy in vivo [8, 9],
sophisticated, expensive technologies. It is difficult to
culture these organisms from clinical specimens, and
reliable serologic tests are not available for the diagnosis
of microsporidiosis [8, 9]. Transmission electron microsco-
py has been the gold standard for definitive diagnosis of
microsporidial infection; molecular methods (most making
use of the polymerase chain reaction) have been developed
as alternative approaches for the laboratory diagnosis of
microsporidiosis [8]. These methods have not been avail-
able in developing countries such as Ethiopia.
The best treatment for microsporidial keratitis has not
been established. Treatment with 0.02% polyhexamethy-
lene biguanide does not offer any significant advantage
over placebo [5]. Microsporidial infections in HIV-infected
individuals may respond to combination of antibiotics and
antiparasitic agents, including topical propamidine isethio-
nate, topical fumagillin, topical fluoroquinolones, oral
albendazole, and/or oral itraconazole. However, treatment
often has been followed by recrudescence of infection [1, 4,
7, 10]. One report describes unmasking of microsporidiosis
infection following HAART-induced immune recovery
[11], likely representing an immune recovery inflammatory
syndrome [12]. Topical steroids in immune-competent
patients with microsporidiosis seem to contribute to the
persistence of infection and may be a predisposing factor in
these cases by creating a localized immunocompromised
state [13].
Although one case has been reported in a patient who
had lived in Mozambique [14], to the best of our
knowledge, no cases have been reported from centers in
Africa to date. In order to better characterize the nature of
this condition, in addition to the previous review of the
available literature on the subject of microsporidial kerati-
tis, we now report the clinical and pathological character-
istics and the outcomes of a cluster of three additional cases
presenting for care in Addis Ababa, Ethiopia during a 5-
month period in 2008.
Methods
We retrospectively reviewed the clinical features, micro-
scopic observations, and treatment response to albendazole
of a cluster of immune-compromised patients with kerato-
conjunctival microsporidiosis seen at the anterior segment
clinic of Menelik II Hospital, the primary cornea and
external diseases center for the Department of Ophthalmol-
ogy, Addis Ababa University. In each case, best-corrected
visual acuity had been measured at 6 m for each eye of each
patient. Clinical findings were based on slit-lamp biomicro-
scopy by a consultant cornea specialist.
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Specimens were obtained and evaluated by the Depart-
ment of Microbiology and Parasitology of Black Lion
Hospital, Addis Ababa University. Conjunctival swabs, as a
minimally invasive first step toward diagnosis, were
collected from each patient suspected of having micro-
sporidiosis and directly smeared on a slide and allowed to
air-dry prior to fixation with methanol. The slides were
stained with the modified trichrome stain solution for
90 min and then rinsed for 10 s with acid alcohol, rinsed
briefly with 95% ethanol, and incubated for 5 min in 95%
ethanol and for 10 min in 100% ethanol. The slides were
air-dried and examined microscopically with oil immersion.
The microsporidial spores stain dark violet against a pale-
green background.
After confirmation of microsporidial keratitis, CD4+ T
cell counts were determined, and highly active antiretroviral
therapy (HAART) initiated or continued. For patients who
failed to improve on HAART alone, either one or two
courses of albendazole was initiated, as alternative treat-
ments were not available in Ethiopia at the time of the
study. Patients’ response to the treatment was evaluated
clinically following treatment.
Results
Among over 3,000 patients seen in the cornea and external
diseases clinic between June 2008 and November 2008
inclusive, three cases of microsporidial infection were
identified, all in patients with HIV/AIDS.
Case 1
A 10-year-old female patient from Addis Ababa, discov-
ered to be HIV seropositive a year previously, presented
with 3 months history of redness, tearing, photophobia, and
reduction of vision of both eyes. Her best-corrected visual
acuity was 6/60 (6/24 with pin hole) and counting fingers at
4 m (no improvement with pin hole) in the right and left
eyes, respectively. She had a healed zoster scar over the left
side of the forehead. The conjunctivae were hyperemic with
ciliary flush. Corneal sensation was diminished bilaterally,
and diffuse epithelial and subepithelial whitish corneal
infiltrates were present (Fig. 1), which stained with
fluorescein.
Prior to her presentation, treatment with gentamicin eye
drops had been followed by marked worsening of visual
acuity, redness, tearing, and photophobia. After initial
treatment with artificial tears, chloramphenicol eye oint-
ment, acyclovir, and topical corticosteroids failed to
improve her condition, a conjunctival swab was taken from
the patient for microscopic investigation, and the CD4+ T
cell count was determined. Light microscopy demonstrated
myriad small, round to oval microsporidial organisms
that stained positively with modified acid-fast methods
(see Fig. 2, left panel). Based on these findings, and a
CD4+ T cell count of 71 cells/μL, she was started on
HAART.
One month after initiating the HAART, the patient
continued to have symptoms of bilateral foreign body
sensation, redness, tearing, and blurred vision, and exam-
ination findings were unchanged. A course of oral
albendazole 200 mg daily for 14 days was initiated.
Following completion of the course, symptoms of redness,
foreign body sensation, and photophobia were markedly
reduced. The visual acuity improved to 6/9 and 6/12 in
right and left eyes respectively, the conjunctivae were white
and quiet, and only scanty intraepithelial white infiltrates
remained in the peripheral corneas. During monthly follow-
up over the next 3 months, no recurrence was observed; the
CD4 count was found to have increased to 189 cells/μL by
that time.
Case 2
A married 40-year-old female from Addis Ababa presented
with a 1-year history of unilateral (left eye) redness,
episodic photophobia, and blurring of vision. She gave
history of having had loss of vision in the right eye
following severe redness, pain, photophobia, and excessive
tearing 2 years prior to her presentation. She denied a
previous history of contact with animals or agricultural
trauma. She was known to be HIV positive, having taken
HAART for the past 4 years, with a recent CD4+ T cell
count of 259 cells/μL. She had not been taking topical
therapies at the time of presentation.
Fig. 1 Slit-lamp photograph showing the slit-lamp findings of
case 1 (intraepithelial corneal infiltrates in a case of microsporidial
keratoconjunctivitis)
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On examination, the visual acuity of the left eye was 6/9.
The bulbar conjunctiva was injected nasally, and the cornea
had yellowish stromal and intraepithelial infiltrates that
stained with fluorescein, although there was no epithelial
defect (findings similar to those illustrated in Fig. 1). A
microscopic examination of a conjunctival swab using light
microscopy demonstrated myriad small, round to oval
microsporidial organisms that stained positively with
modified acid-fast methods, confirming microsporidial
keratitis (findings similar to those illustrated in Fig. 2).
After 2 weeks of treatment with albendazole 400 mg twice
daily, while continuing HAART, all the ocular complaints
disappeared, and the corneal opacity was less dense as
compared to prior to initiating the albendazole treatment.
Similar to the first case, the patient had no recurrence of
signs or symptoms over 3 months follow-up.
Case 3
A 24-year-old woman from Addis Ababa presented with a
7-month history of bilateral foreign body sensation,
redness, tearing, and reduction in vision, which had not
improved with 1 month of topical corticosteroids. She was
known to be HIV positive, but had not received HAART
previously. She had no history of contact with animals or
agricultural trauma. At initial presentation, her visual acuity
was 6/24 and 6/9 on the right and left eyes, respectively. In
each eye, the conjunctivae were hyperaemic, and there were
diffuse intraepithelial whitish infiltrates over the cornea
with punctate fluorescein staining. Light microscopy of a
conjunctival swab revealed myriad small, round to oval
microsporidial organisms that stained positively with
modified acid-fast method for microsporidia.
After the CD4+ T cell count was found to be 45 cells/μL,
HAART was initiated 1 day after taking the conjunctival
swab. One month after HAART, there was little symptomatic
or objective improvement in the ophthalmic findings, and the
CD4+ T cell count had improved to 179 cells/μL. Thereafter,
she was treated with albendazole 400 mg twice daily for
2 weeks. At the second month, she presented with worsening
of redness and severe foreign body sensation and no visual
improvement; she developed a corneal epithelial defect over
the left eye, and the preexisting intraepithelial lesions had
become more flocculent in appearance (Fig. 3). Although the
corneal epithelial defect healed after patching, the clinical
findings failed to resolve after a second course of albenda-
zole, unlike the other two cases. However, the symptoms and
signs eventually subsided. On suspicion that the continued
inflammation despite albendazole was the result of an
immune recovery inflammatory syndrome, additional 2-
week courses of albendazole were attempted, after which
symptoms improved but relapsed 3–4 months after each
course.
Fig. 2 Microsporidial spores
staining dark violet against a
pale-green background in a
conjunctival swab specimen
from case 3. Microsporidial
spores (large arrow) are seen as
well-defined oval reddish bodies
with a dark staining of the
narrow end of the spore (black)
or a waistband (white) closer to
the tip of narrow end. Also seen
are the unstained blue spores
(small arrow) which possibly
are immature or degenerating
spores (1% acid-fast
stain, ×1,000)
Fig. 3 Slit-lamp photograph showing the slit-lamp findings of
case 3 (intraepithelial corneal infiltrates in a case of microsporidial
keratoconjunctivitis)
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Discussion
The first case of microsporidiosis in an HIV-infected
individual was reported in 1985 [1]; since then, over 400
cases have been reported. Microsporidiosis appears to occur
most commonly in severely immunodeficient individuals,
especially patients having CD4 + T-lymphocyte counts <100
cells/μL [7, 12, 15], although it is a rare condition even
among these individuals. As in our cases, microsporidiosis
consistently has been reported as limited to the corneal
epithelium in case reports from immunodeficient patients
[3, 6].
Although the second case was on HAART for 4 years
before presentation, the other two cases presented with a
CD4+ T cell count <100 cells/μL. We hypothesize that the
lesser degree of ocular discomfort and less dramatic
physical findings in the second patient might have been
related to her successful treatment with antiretroviral
therapy, although a small series such as this one is unable
to confirm such a hypothesis. If so, early diagnosis of HIV
infection and initiation of HAART may improve the clinical
course of microsporidial keratoconjunctivitis in some cases,
in addition to the numerous other benefits of such therapy
for patients with advanced HIV/AIDS [11, 15]. Such
benefits most likely would outweigh the potential to
develop an immune recovery inflammatory syndrome in
occasional cases [12], such as may have happened in
patient 3 2 months after starting HAART.
Detection of microsporidiosis classically has relied on
electron microscopy and the histopathology of corneal or
conjunctival biopsy specimens, the latter being essential for
accurate speciation. In our report the microsporidial spores
were identified using the simple, inexpensive approach of
using modified acid-fast staining technique applied to a
specimen taken from a conjunctival swab, a minimally
invasive approach that is potentially an appropriate first
step toward the diagnosis of microsporidiosis in settings
with limited resources. While in our cases simple conjunc-
tival swabs yielded the diagnosis, the approach likely
would have lesser sensitivity and specificity than more
invasive approaches; corneal scraping and/or conjunctival
biopsy likely would be needed in some instances to make
the diagnosis.
Therapeutically, there is no standard medical therapy for
corneal microsporidiosis. However, the most frequently
used approach has been topical fumagillin [15] and/or oral
albendazole, which have been associated with improvement
in many but not all cases [16, 17]. Topical fluoroquinolone
monotherapy also has been reported as a useful treatment
option for microsporidial keratitis [10]. There also have
been reports of response of cases of keratoconjunctivitis to
topical brolene [18] or oral itraconazole [19]. Our experi-
ence demonstrates successful treatment in two of three
cases and what we interpret as partial success in the third
using albendazole, an inexpensive treatment (less than US
$1 per course in Ethiopia), which is widely available and
suitable for use in resource-limited settings. Laboratory
determination of microsporidial sensitivity potentially could
identify alternative regimens for strains and alternate
species which prove not to be sensitive to treatment with
albendazole; sensitivity testing was not available in our
setting, so we were unable to evaluate case 3 for resistance.
Conclusion
Microsporidiosis should be considered in the differential
diagnosis of chronic keratoconjunctivitis in immunodefi-
cient patients. Reciprocally, patients with microsporidial
keratoconjunctivitis should be evaluated for possible
immunodeficiency syndromes such as HIV/AIDS, given
the known association between these conditions, and the
increasing availability of effective treatment for HIV/AIDS.
Based on our small sample and the limited reported
experience in the literature, albendazole, which is inexpen-
sive and widely available, is a practical treatment approach
when the diagnosis of microsporidial keratoconjunctivitis is
recognized in a resource-constrained setting.
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